Search

Your search keyword '"Cyran, Clemens"' showing total 354 results
Start Over Author "Cyran, Clemens" Publication Year Range Last 10 years
354 results on '"Cyran, Clemens"'

3. [68Ga]Ga-FAPI-46 PET/CT for penile cancer – a feasibility study

Author

Eismann, Lennert, Ledderose, Stephan T., Enzinger, Benazir, Berg, Elena, Westhofen, Thilo, Rodler, Severin, Schulz, Gerald B., Toms, Johannes, Holzgreve, Adrien, Gildehaus, Franz J., Brendel, Matthias, Cyran, Clemens C., Unterrainer, Marcus, Stief, Christian G., Bartenstein, Peter, Schlenker, Boris, and Unterrainer, Lena M.

Published
2024
Full Text
View/download PDF

6. [68 Ga]Ga-FAPI-46 PET/CT for locoregional lymph node staging in urothelial carcinoma of the bladder prior to cystectomy: initial experiences from a pilot analysis

Author

Unterrainer, Lena M., Eismann, Lennert, Lindner, Simon, Gildehaus, Franz-Josef, Toms, Johannes, Casuscelli, Jozefina, Holzgreve, Adrien, Kunte, Sophie C., Cyran, Clemens C., Menold, Paula, Karl, Alexander, Unterrainer, Marcus, Ledderose, Stephan T., Stief, Christian G., Bartenstein, Peter, Kretschmer, Alexander, and Schulz, Gerald B.

Published
2024
Full Text
View/download PDF

9. Next-generation PET/CT imaging in meningioma—first clinical experiences using the novel SSTR-targeting peptide [18F]SiTATE

Author

Unterrainer, Marcus, Kunte, Sophie C., Unterrainer, Lena M., Holzgreve, Adrien, Delker, Astrid, Lindner, Simon, Beyer, Leonie, Brendel, Matthias, Kunz, Wolfgang G., Winkelmann, Michael, Cyran, Clemens C., Ricke, Jens, Jurkschat, Klaus, Wängler, Carmen, Wängler, Björn, Schirrmacher, Ralf, Belka, Claus, Niyazi, Maximilian, Tonn, Joerg-Christian, Bartenstein, Peter, and Albert, Nathalie L.

Published
2023
Full Text
View/download PDF

11. Validation of the SSTR-RADS 1.0 for the structured interpretation of SSTR-PET/CT and treatment planning in neuroendocrine tumor (NET) patients

Author

Grawe, Freba, Ebner, Ricarda, Geyer, Thomas, Beyer, Leonie, Winkelmann, Michael, Sheikh, Gabriel T., Eschbach, Ralf, Schmid-Tannwald, Christine, Cyran, Clemens C., Ricke, Jens, Bartenstein, Peter, Heimer, Maurice M., Faggioni, Lorenzo, Spitzweg, Christine, Fabritius, Matthias P., Auernhammer, Christoph J., and Ruebenthaler, Johannes

Published
2023
Full Text
View/download PDF

12. Attitudes and perceptions of radiologists towards online (virtual) oncologic multidisciplinary team meetings during the COVID-19 pandemic—a survey of the European Society of Oncologic Imaging (ESOI)

Author

Bonanno, Nathania, Cioni, Dania, Caruso, Damiano, Cyran, Clemens C., Dinkel, Julien, Fournier, Laure, Gourtsoyianni, Sofia, Hoffmann, Ralf-Thorsten, Laghi, Andrea, Martincich, Laura, Mayerhoefer, Marius E., Zamboni, Giulia A., Sala, Evis, Schlemmer, Heinz-Peter, Neri, Emanuele, and D’Anastasi, Melvin

Published
2023
Full Text
View/download PDF

13. Correction to: Next‑generation PET/CT imaging in meningioma—first clinical experiences using the novel SSTR‑targeting peptide [18F]SiTATE

Author

Unterrainer, Marcus, Kunte, Sophie C., Unterrainer, Lena M., Holzgreve, Adrien, Delker, Astrid, Lindner, Simon, Beyer, Leonie, Brendel, Matthias, Kunz, Wolfgang G., Winkelmann, Michael, Cyran, Clemens C., Ricke, Jens, Jurkschat, Klaus, Wängler, Carmen, Wängler, Björn, Schirrmacher, Ralf, Belka, Claus, Niyazi, Maximilian, Tonn, Joerg‑Christian, Bartenstein, Peter, and Albert, Nathalie L.

Published
2023
Full Text
View/download PDF

14. Feasibility of [68Ga]Ga-FAPI-46 PET/CT for detection of nodal and hematogenous spread in high-grade urothelial carcinoma

Author

Unterrainer, Lena M., Lindner, Simon, Eismann, Lennert, Casuscelli, Jozefina, Gildehaus, Franz-Josef, Bui, Vinh Ngoc, Albert, Nathalie L., Holzgreve, Adrien, Beyer, Leonie, Todica, Andrei, Brendel, Matthias, Cyran, Clemens C., Karl, Alexander, Stief, Christian G., Ledderose, Stephan T., Unterrainer, Marcus, Bartenstein, Peter, Wenter, Vera, and Kretschmer, Alexander

Published
2022
Full Text
View/download PDF

15. Imaging of pancreatic neuroendocrine tumors

Author

Berger, Frank, primary, Ingenerf, Maria, additional, Auernhammer, Christoph J, additional, Cyran, Clemens, additional, Ebner, Ricarda, additional, Zacherl, Mathias, additional, Ricke, Jens, additional, and Schmid-Tannwald, Christine, additional

Published
2024
Full Text
View/download PDF

17. Complicated Carotid Artery Plaques and Risk of Recurrent Ischemic Stroke or TIA

Author

Kopczak, Anna, Schindler, Andreas, Sepp, Dominik, Bayer-Karpinska, Anna, Malik, Rainer, Koch, Mia L., Zeller, Julia, Strecker, Christoph, Janowitz, Daniel, Wollenweber, Frank A., Hempel, Johann-Martin, Boeckh-Behrens, Tobias, Cyran, Clemens C., Helck, Andreas, Harloff, Andreas, Ziemann, Ulf, Poli, Sven, Poppert, Holger, Saam, Tobias, and Dichgans, Martin

Published
2022
Full Text
View/download PDF

18. 68Ga-EMP-100 PET/CT—a novel ligand for visualizing c-MET expression in metastatic renal cell carcinoma—first in-human biodistribution and imaging results

Author

Mittlmeier, Lena M., Todica, Andrei, Gildehaus, Franz-Josef, Unterrainer, Marcus, Beyer, Leonie, Brendel, Matthias, Albert, Nathalie L., Ledderose, Stephan T., Vettermann, Franziska J., Schott, Melanie, Rodler, Severin, Marcon, Julian, Ilhan, Harun, Cyran, Clemens C., Stief, Christian G., Staehler, Michael, and Bartenstein, Peter

Published
2022
Full Text
View/download PDF

21. Novel intravascular tantalum oxide-based contrast agent achieves improved vascular contrast enhancement and conspicuity compared to Iopamidol in an animal multiphase CT protocol.

Author

Heimer, Maurice M., Sun, Yuxin, Grosu, Sergio, Cyran, Clemens C., Bonitatibus Jr, Peter J., Okwelogu, Nikki, Bales, Brian C., Meyer, Dan E., and Yeh, Benjamin M.

Subjects
CONTRAST media, VENA cava inferior, THORACIC arteries, TANTALUM oxide, COMPUTED tomography
Abstract

Background: To assess thoracic vascular computed tomography (CT) contrast enhancement of a novel intravenous tantalum oxide nanoparticle contrast agent (carboxybetaine zwitterionic tantalum oxide, TaCZ) compared to a conventional iodinated contrast agent (Iopamidol) in a rabbit multiphase protocol. Methods: Five rabbits were scanned inside a human-torso-sized encasement on a clinical CT system at various scan delays after intravenous injection of 540 mg element (Ta or I) per kg of bodyweight of TaCZ or Iopamidol. Net contrast enhancement of various arteries and veins, as well as image noise, were measured. Randomized scan series were reviewed by three independent readers on a clinical workstation and assessed for vascular conspicuity and image artifacts on 5-point Likert scales. Results: Overall, net vascular contrast enhancement achieved with TaCZ was superior to Iopamidol (p ≤ 0.036 with the exception of the inferior vena cava at 6 s (p = 0.131). Vascular contrast enhancement achieved with TaCZ at delays of 6 s, 40 s, and 75 s was superior to optimum achieved Iopamidol contrast enhancement at 6 s (p ≤ 0.036. Vascular conspicuity was higher for TaCZ in 269 of 300 (89.7%) arterial and 269 of 300 (89.7%) venous vessel assessments, respectively (p ≤ 0.005), with substantial inter-reader reliability (κ = 0.61; p < 0.001) and strong positive monotonic correlation between conspicuity scores and contrast enhancement measurements (ρ = 0.828; p < 0.001). Conclusion: TaCZ provides absolute and relative contrast advantages compared to Iopamidol for improved visualization of thoracic arteries and veins in a multiphase CT protocol. Relevance statement: The tantalum-oxide nanoparticle is an experimental intravenous CT contrast agent with superior cardiovascular and venous contrast capacity per injected elemental mass in an animal model, providing improved maximum contrast enhancement and prolonged contrast conspicuity. Further translational research on promising high-Z and nanoparticle contrast agents is warranted. Key Points: There have been no major advancements in intravenous CT contrast agents over decades. Iodinated CT contrast agents require optimal timing for angiography and phlebography. Tantalum-oxide demonstrated increased CT attenuation per elemental mass compared to Iopamidol. Nanoparticle contrast agent design facilitates prolonged vascular conspicuity. [ABSTRACT FROM AUTHOR]

Published
2024
Full Text
View/download PDF

22. [68Ga]Ga-FAPI-46 PET/CT for penile cancer – a feasibility study.

Author

Eismann, Lennert, Ledderose, Stephan T., Enzinger, Benazir, Berg, Elena, Westhofen, Thilo, Rodler, Severin, Schulz, Gerald B., Toms, Johannes, Holzgreve, Adrien, Gildehaus, Franz J., Brendel, Matthias, Cyran, Clemens C., Unterrainer, Marcus, Stief, Christian G., Bartenstein, Peter, Schlenker, Boris, and Unterrainer, Lena M.

Subjects
PENILE cancer, SURGICAL therapeutics, LYMPHATIC metastasis, TREATMENT delay (Medicine), LYMPH nodes, POSITRON emission tomography
Abstract

Purpose: Penile cancer is a rare entity and has a good prognosis in localized stage. Delayed surgical treatment of lymphatic disease is associated with poor overall survival but conventional imaging cannot detect occult lymph node metastasis sufficiently. Imaging cancer related fibroblasts has shown promising results as non-invasive staging tool in various tumor entities but has not yet been evaluated in penile cancer. Methods: In this single-center pilot study, patients planned for surgical treatment for penile cancer underwent preoperatively [68Ga]Ga-FAPI-46 PET/CT. Post-operative histopathology was compared to [68Ga]Ga-FAPI-46 PET/CT results. Results: From January 2022 to June 2022, a total number 11 patients with histopathologically proven penile cancer underwent surgery and received [68Ga]Ga-FAPI-46 PET/CT prior therapy. 8 primary tumor sites and 4 lymph node regions were analyzed. FAPI uptake was increased on primary tumor site (SUVmax 16.2 (9.1 – 25.8)). Histopathological proven lymph node regions showed highly increased FAPI uptakes (SUVmax 17.9 (16.4 – 23.5) on [68Ga]Ga-FAPI-46 PET/CT. Conclusion: In this first pilot cohort, there were no false-positive FAPI uptake which might allow the detection of occult lymph node metastasis by [68Ga]Ga-FAPI-46 PET/CT and might consequently lead to omitting lymph node regions during surgery that had no increased FAPI uptake pre-operatively. [ABSTRACT FROM AUTHOR]

Published
2024
Full Text
View/download PDF

23. Functional maturation and longitudinal imaging of intraportal neonatal porcine islet grafts in genetically diabetic pigs

Author

Pilz, Johanna, primary, Gloddek, Nicol, additional, Lindheimer, Felix, additional, Lindner, Magdalena J., additional, Puhr-Westerheide, Daniel, additional, Ümütlü, Muzzafer, additional, Cyran, Clemens, additional, Seidensticker, Max, additional, Lindner, Richard, additional, Kraetzl, Martin, additional, Renner, Simone, additional, Merkus, Daphne, additional, Teupser, Daniel, additional, Bartenstein, Peter, additional, Ziegler, Sibylle I., additional, Wolf, Eckhard, additional, and Kemter, Elisabeth, additional

Published
2024
Full Text
View/download PDF

24. Dosimetry and optimal scan time of [18F]SiTATE-PET/CT in patients with neuroendocrine tumours

Author

Beyer, Leonie, Gosewisch, Astrid, Lindner, Simon, Völter, Friederike, Mittlmeier, Lena M., Tiling, Reinhold, Brendel, Matthias, Cyran, Clemens C., Unterrainer, Marcus, Rübenthaler, Johannes, Auernhammer, Christoph J., Spitzweg, Christine, Böning, Guido, Gildehaus, F. J., Jurkschat, Klaus, Wängler, Carmen, Wängler, Björn, Schirrmacher, Ralf, Wenter, Vera, Todica, Andrei, Bartenstein, Peter, and Ilhan, Harun

Published
2021
Full Text
View/download PDF

27. [68 Ga]Ga-FAPI-46 PET/CT for locoregional lymph node staging in urothelial carcinoma of the bladder prior to cystectomy: initial experiences from a pilot analysis.

Author

Unterrainer, Lena M., Eismann, Lennert, Lindner, Simon, Gildehaus, Franz-Josef, Toms, Johannes, Casuscelli, Jozefina, Holzgreve, Adrien, Kunte, Sophie C., Cyran, Clemens C., Menold, Paula, Karl, Alexander, Unterrainer, Marcus, Ledderose, Stephan T., Stief, Christian G., Bartenstein, Peter, Kretschmer, Alexander, and Schulz, Gerald B.

Subjects
POSITRON emission tomography, TRANSITIONAL cell carcinoma, LYMPH nodes, UROTHELIUM, CYSTECTOMY, BLADDER, URINARY organs
Abstract

Introduction: [68 Ga]Ga-FAPI-46 PET/CT is a novel hybrid imaging method that previously showed additional diagnostic value in the assessment of distant urothelial carcinoma lesions. We hypothesized that patients with bladder cancer benefit from [68 Ga]Ga-FAPI-46 PET/CT prior to radical cystectomy for locoregional lymph node staging. Materials and methods: Eighteen patients underwent [68 Ga]Ga-FAPI-46 PET/CT for evaluation of lymph node (LN) status in predefined LN regions. Two hundred twenty-nine intraoperatively removed LN served as histopathological reference standard. Results: Urothelial carcinoma (UC) spread was found in ten LN in seven different regions (14.3%). Hereby, [68 Ga]Ga-FAPI-46 PET/CT was positive in four out of seven regions (57.1%) and showed significantly increased FAPI uptake compared to non-pathological regions. In the remaining three out of seven (42.9%) regions, [68 Ga]Ga-FAPI-46 PET/CT was rated negative since no pathological increased FAPI uptake was detected or the proximity of the urinary tract prevented a differentiation from physiological uptake. CT was inconspicuous in these three regions. In total, two FAP-positive LN regions were found without histopathological counterpart. Overall, sensitivity, specificity, positive predictive value, and negative predictive value were 57.1%, 95.2%, 66.7%, and 93.0% for PET imaging. Conclusion: In summary, this innovative [68 Ga]Ga-FAPI-46 PET/CT method showed high specificity and negative predictive value in patients with bladder UC with a future potential to optimize therapy planning. [ABSTRACT FROM AUTHOR]

Published
2024
Full Text
View/download PDF

29. Multislice PET/CT in Neuroendocrine Tumors

Author

Pöpperl, Gabriele, Cyran, Clemens, Kauczor, Hans-Ulrich, Series Editor, Parizel, Paul M., Series Editor, Peh, Wilfred C. G., Series Editor, Brady, Luther W., Honorary Editor, Lu, Jiade J., Series Editor, Nikolaou, Konstantin, editor, Bamberg, Fabian, editor, Laghi, Andrea, editor, and Rubin, Geoffrey D., editor

Published
2019
Full Text
View/download PDF

30. Identification of impactful imaging biomarker: Clinical applications for breast and prostate carcinoma

Author

Bäuerle, Tobias, additional, Dietzel, Matthias, additional, Pinker, Katja, additional, Bonekamp, David, additional, Zhang, Kevin S., additional, Schlemmer, Heinz-Peter, additional, Bannas, Peter, additional, Cyran, Clemens C., additional, Eisenblätter, Michel, additional, Hilger, Ingrid, additional, Jung, Caroline, additional, Schick, Fritz, additional, Wegner, Franz, additional, and Kiessling, Fabian, additional

Published
2023
Full Text
View/download PDF

41. MP50-03 [ 68 Ga]Ga-FAPI-46 PET/CT PRIOR TO SURGERY IN SQUAMOUS PENILE CANCER – PRELIMINARY CLINICAL RESULTS

Author

Eismann, Lennert, primary, Toms, Johannes, additional, Holzgreve, Adrien, additional, Berg, Elena, additional, Schleifele, Maximilian, additional, Rodler, Severin, additional, Gildehaus, Franz-Josef, additional, Brendel, Matthias, additional, Albert, Nathalie, additional, Cyran, Clemens, additional, Kazmierczak, Philipp, additional, Kunz, Wolfgang, additional, Ledderose, Stephan, additional, Stief, Christian, additional, Bartenstein, Peter, additional, Unterrainer, Marcus, additional, Schlenker, Boris, additional, and Unterrainer, Lena, additional

Published
2023
Full Text
View/download PDF

47. Next-generation PET/CT imaging in meningioma—first clinical experiences using the novel SSTR-targeting peptide [18F]SiTATE.

Author

Unterrainer, Marcus, Kunte, Sophie C., Unterrainer, Lena M., Holzgreve, Adrien, Delker, Astrid, Lindner, Simon, Beyer, Leonie, Brendel, Matthias, Kunz, Wolfgang G., Winkelmann, Michael, Cyran, Clemens C., Ricke, Jens, Jurkschat, Klaus, Wängler, Carmen, Wängler, Björn, Schirrmacher, Ralf, Belka, Claus, Niyazi, Maximilian, Tonn, Joerg-Christian, and Bartenstein, Peter

Subjects
COMPUTED tomography, PEPTIDES, MENINGIOMA, POSITRON emission tomography, BONE marrow, SOMATOSTATIN receptors
Abstract

Background: Somatostatin-receptor (SSTR)-targeted PET/CT provides important clinical information in addition to standard imaging in meningioma patients. [18F]SiTATE is a novel, 18F-labeled SSTR-targeting peptide with superior imaging properties according to preliminary data. We provide the first [18F]SiTATE PET/CT data of a large cohort of meningioma patients. Methods: Patients with known or suspected meningioma undergoing [18F]SiTATE PET/CT were included. Uptake intensity (SUV) of meningiomas, non-meningioma lesions, and healthy organs were assessed using a 50% isocontour volume of interest (VOI) or a spherical VOI, respectively. Also, trans-osseous extension on PET/CT was assessed. Results: A total of 107 patients with 117 [18F]SiTATE PET/CT scans were included. Overall, 231 meningioma lesions and 61 non-meningioma lesions (e.g., post-therapeutic changes) were analyzed. Physiological uptake was lowest in healthy brain tissue, followed by bone marrow, parotid, and pituitary (SUVmean 0.06 ± 0.04 vs. 1.4 ± 0.9 vs. 1.6 ± 1.0 vs. 9.8 ± 4.6; p < 0.001). Meningiomas showed significantly higher uptake than non-meningioma lesions (SUVmax 11.6 ± 10.6 vs. 4.0 ± 3.3, p < 0.001). Meningiomas showed significantly higher uptake than non-meningioma lesions (SUVmax 11.6±10.6 vs. 4.0±3.3, p<0.001). 93/231 (40.3%) meningiomas showed partial trans-osseous extension and 34/231 (14.7%) predominant intra-osseous extension. 59/231 (25.6%) meningioma lesions found on PET/CT had not been reported on previous standard imaging. Conclusion: This is the first PET/CT study using an 18F-labeled SSTR-ligand in meningioma patients: [18F]SiTATE provides extraordinary contrast in meningioma compared to healthy tissue and non-meningioma lesions, which leads to a high detection rate of so far unknown meningioma sites and osseous involvement. Having in mind the advantageous logistic features of 18F-labeled compared to 68Ga-labeled compounds (e.g., longer half-life and large-badge production), [18F]SiTATE has the potential to foster a widespread use of SSTR-targeted imaging in neuro-oncology. [ABSTRACT FROM AUTHOR]

Published
2023
Full Text
View/download PDF

48. Comparison of somatostatin receptor expression in patients with neuroendocrine tumours with and without somatostatin analogue treatment imaged with [18F]SiTATE

Author

Eschbach, Ralf S., primary, Hofmann, Markus, additional, Späth, Lukas, additional, Sheikh, Gabriel T., additional, Delker, Astrid, additional, Lindner, Simon, additional, Jurkschat, Klaus, additional, Wängler, Carmen, additional, Wängler, Björn, additional, Schirrmacher, Ralf, additional, Tiling, Reinhold, additional, Brendel, Matthias, additional, Wenter, Vera, additional, Dekorsy, Franziska J., additional, Zacherl, Mathias J., additional, Todica, Andrei, additional, Ilhan, Harun, additional, Grawe, Freba, additional, Cyran, Clemens C., additional, Unterrainer, Marcus, additional, Rübenthaler, Johannes, additional, Knösel, Thomas, additional, Paul, Tanja, additional, Boeck, Stefan, additional, Westphalen, Christoph Benedikt, additional, Spitzweg, Christine, additional, Auernhammer, Christoph J., additional, Bartenstein, Peter, additional, Unterrainer, Lena M., additional, and Beyer, Leonie, additional

Published
2023
Full Text
View/download PDF

Catalog

Books, media, physical & digital resources
See catalog results